ATE462706T1 - 7h-pyrroloä2,3-düpyrimidinderivate sowie deren therapeutisch annehmbare salze, pharmazeutische zubereitungen, die diese enthalten, und verfahren zur herstellung des wirkstoffs - Google Patents

7h-pyrroloä2,3-düpyrimidinderivate sowie deren therapeutisch annehmbare salze, pharmazeutische zubereitungen, die diese enthalten, und verfahren zur herstellung des wirkstoffs

Info

Publication number
ATE462706T1
ATE462706T1 AT05739554T AT05739554T ATE462706T1 AT E462706 T1 ATE462706 T1 AT E462706T1 AT 05739554 T AT05739554 T AT 05739554T AT 05739554 T AT05739554 T AT 05739554T AT E462706 T1 ATE462706 T1 AT E462706T1
Authority
AT
Austria
Prior art keywords
producing
acceptable salts
pharmaceutical preparations
preparations containing
derivatives
Prior art date
Application number
AT05739554T
Other languages
German (de)
English (en)
Inventor
Janos Szolcsanyi
Laszlo Orfi
Gyoergy Keri
Frigyes Waczek
Erika Pinter
Zsuzsanna Helyes
Tamas Szuets
Jozsef Nemeth
Original Assignee
Janos Szolcsanyi
Laszlo Orfi
Gyoergy Keri
Frigyes Waczek
Erika Pinter
Zsuzsanna Helyes
Tamas Szuets
Jozsef Nemeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janos Szolcsanyi, Laszlo Orfi, Gyoergy Keri, Frigyes Waczek, Erika Pinter, Zsuzsanna Helyes, Tamas Szuets, Jozsef Nemeth filed Critical Janos Szolcsanyi
Application granted granted Critical
Publication of ATE462706T1 publication Critical patent/ATE462706T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05739554T 2004-04-29 2005-04-25 7h-pyrroloä2,3-düpyrimidinderivate sowie deren therapeutisch annehmbare salze, pharmazeutische zubereitungen, die diese enthalten, und verfahren zur herstellung des wirkstoffs ATE462706T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0400891A HUP0400891A2 (en) 2004-04-29 2004-04-29 7h-pyrrolo[2,3-d]pyrimidine derivatives, their pharmaceutically acceptable salts, pharmaceutical compositions containing them and process for the production of the compounds
PCT/HU2005/000040 WO2005105804A1 (en) 2004-04-29 2005-04-25 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES, AS WELL AS THEIR THERAPEUTICALLY ACCEPTABLE SALTS, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND PROCESS FOR PRODUCTION THE ACTIVE AGENT

Publications (1)

Publication Number Publication Date
ATE462706T1 true ATE462706T1 (de) 2010-04-15

Family

ID=89982174

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05739554T ATE462706T1 (de) 2004-04-29 2005-04-25 7h-pyrroloä2,3-düpyrimidinderivate sowie deren therapeutisch annehmbare salze, pharmazeutische zubereitungen, die diese enthalten, und verfahren zur herstellung des wirkstoffs

Country Status (13)

Country Link
US (1) US20080214583A1 (https=)
EP (1) EP1756110B1 (https=)
JP (1) JP2007534737A (https=)
KR (1) KR20070047737A (https=)
CN (1) CN1972946A (https=)
AT (1) ATE462706T1 (https=)
AU (1) AU2005238287A1 (https=)
CA (1) CA2564277A1 (https=)
DE (1) DE602005020281D1 (https=)
HU (1) HUP0400891A2 (https=)
IL (1) IL178906A0 (https=)
RU (1) RU2391344C2 (https=)
WO (1) WO2005105804A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150133426A1 (en) * 2012-05-21 2015-05-14 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyrimidines
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
EP3194399B1 (en) * 2014-09-17 2019-04-10 Pécsi Tudományegyetem New agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders
RU2603770C2 (ru) * 2014-11-28 2016-11-27 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Замещенные пиразинопиримидиноны как блокаторы trpa1 каналов, фармацевтическая композиция, способы их получения и применения
CN110483526B (zh) * 2019-09-09 2021-10-01 辽宁大学 含芳基腙结构的吡唑并[1,5-a]嘧啶类衍生物及其应用
CN119613409B (zh) * 2024-12-05 2026-04-17 浙江工业大学 吡咯并[2,3-d]嘧啶衍生物及其在制备抗炎药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2818676A1 (de) * 1978-04-27 1979-11-08 Troponwerke Gmbh & Co Kg Substituierte 5,6-dimethylpyrrolo 2,3-d pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69906511T2 (de) * 1998-05-19 2004-01-29 Otsuka Pharma Co Ltd PYRAZOLO[1,5-a]PYRIMIDINE
RU2001111033A (ru) * 1998-09-18 2003-05-20 Басф Акциенгезелльшафт (De) Пирролопиримидины в качестве ингибиторов протеинкиназ
EP1382339B1 (en) * 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
BRPI0514094A (pt) * 2004-08-02 2008-05-27 Osi Pharm Inc composto, composição, e, método de tratamento de distúrbio hiperproliferativo

Also Published As

Publication number Publication date
AU2005238287A1 (en) 2005-11-10
CA2564277A1 (en) 2005-11-10
HUP0400891A2 (en) 2006-04-28
US20080214583A1 (en) 2008-09-04
EP1756110B1 (en) 2010-03-31
RU2391344C2 (ru) 2010-06-10
WO2005105804A1 (en) 2005-11-10
HU0400891D0 (en) 2004-07-28
EP1756110A1 (en) 2007-02-28
IL178906A0 (en) 2007-03-08
RU2006141393A (ru) 2008-06-10
CN1972946A (zh) 2007-05-30
JP2007534737A (ja) 2007-11-29
DE602005020281D1 (de) 2010-05-12
KR20070047737A (ko) 2007-05-07

Similar Documents

Publication Publication Date Title
AR029011A1 (es) Tiazoles e imidazo[4,5-b]piridinas, un proceso para su produccion, una composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento
BRPI0409314A (pt) derivados de 2-aminopirimidina e seu uso médico
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
BRPI0410477A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto
BRPI0409427A (pt) composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
ATE524443T1 (de) Bicyclische inhibitoren von mek und verfahren zu deren herstellung
SE0100567D0 (sv) Compounds
PT1326613E (pt) Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos
SE0104340D0 (sv) New compounds
BRPI0513864A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, sua utilização e método para o tratamento e/ou profilaxia de enfermidades
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
NO20060113L (no) Pyrrolo(3,4-c)pyrazolderivater aktive som kinase inhibitorer
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
BR0316690A (pt) Composto, prodroga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
ATE336997T1 (de) Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
BRPI0512253A (pt) composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
ATE415410T1 (de) Pharmazeutische zusammensetzung zur behandlung von psoriasis und anderen hautkrankheiten
BRPI0411503A (pt) composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
DE60215313D1 (de) Indolderivate und deren verwendung als gnrh antagonisten
BRPI0512252A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
PT1124841E (pt) Fenil-alcenoil-guanidinas processo para a sua preparacao sua utilizacao como medicamentos ou meios de diagnostico bem como composicao farmaceutica que as contem
ECSP055844A (es) Nuevos compuestos triciclicos
ATE462706T1 (de) 7h-pyrroloä2,3-düpyrimidinderivate sowie deren therapeutisch annehmbare salze, pharmazeutische zubereitungen, die diese enthalten, und verfahren zur herstellung des wirkstoffs
ATE402707T1 (de) Imidazoä1,5aütriazoloä1,5dübenzodiazepin- derivative zur behandlung kognitiver störungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties